{
    "clinical_study": {
        "@rank": "119254", 
        "arm_group": [
            {
                "arm_group_label": "Iocide Oral Rinse", 
                "arm_group_type": "Active Comparator", 
                "description": "Iocide Oral Rinse once daily 30 second rinse for 24 weeks"
            }, 
            {
                "arm_group_label": "Placebo Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Once daily 30 second rinse for 24 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to explore the efficacy of Iocide oral rinse in a  human\n      clinical trial of gingivitis. Iocide oral rinse will be evaluated against a placebo rinse.\n      Indices for gingivitis, plaque and bleeding will be scored and blood tests will be performed\n      to determine the effect of the antimicrobial oral rinse on relative levels of biological\n      markers of inflammation."
        }, 
        "brief_title": "Efficacy of Iocide Oral Rinse Against Gingival Inflammation", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Gingivitis", 
            "Investigation of Biological Markers of Inflammation"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Gingivitis", 
                "Inflammation"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects shall meet all of the following inclusion criteria to be eligible for\n        participation in this study:\n\n          -  Males or non-pregnant females of at least 18 years of age, and in good general\n             health, as determined by Investigator;\n\n          -  Have at least 16 natural, gradable teeth and good dental health, as determined by\n             Investigator;\n\n          -  Have > 25% sites with Gingival Index (GI) scores of > 2 at Visits 1 and 2;\n\n          -  Have Plaque Index (PI) scores of > 1 on > 50% of sites;\n\n          -  Use of effective method of contraception for the duration of the study or permanently\n             sterilized;\n\n          -  Able and willing to comply with study requirements including following instructions\n             on study treatment and returning for follow-up visits as required by the protocol;\n\n          -  Have full understanding of all elements of, and signature and dating of the written\n             informed consent prior to the initiation of protocol specified procedures;\n\n          -  Females with childbearing potential must have a negative pregnancy test before and\n             during the study period. Sexually active females must be using an effective form of\n             birth control or abstinence. These methods include oral contraceptives (\"the pill\"),\n             an intrauterine device (IUD), levonogestrol implants (Norplant\u00ae), medroxyprogesterone\n             acetate injections (Depo-provera\u00ae) or contraceptive foam with a condom.\n\n        Exclusion Criteria:\n\n        Subjects meeting any of the following exclusion criteria will not be eligible for\n        participation in this study:\n\n          -  History, or current evidence, of any significant acute or chronic subject-reported\n             medical or psychiatric condition that, in the opinion of the Investigator, would\n             render examination difficult or invalid or prevent the subject from active study\n             participation;\n\n          -  \u226424% of sites with GI score >2;\n\n          -  Thyroid peroxidase antibody (TPOab) positive >34;\n\n          -  Screening serum level of thyroid stimulating hormone (TSH) <0.45 or >4.5;\n\n          -  Treatment with antibiotic within the one (1) month period prior to the screening\n             examination;\n\n          -  History of heart murmur, history of rheumatic fever, valvular disease, prosthetic\n             implant or any other condition requiring antibiotic premedication;\n\n          -  History of thyroid disease;\n\n          -  Purported sensitivity or allergy to iodine;\n\n          -  Known sensitivity or allergy to shellfish;\n\n          -  History of diabetes;\n\n          -  History of autoimmune disease;\n\n          -  Gross oral pathology (periodontal disease, rampant caries, tissue damage created by\n             poor oral care or treatment, soft or hard tissue tumors) that, in the opinion of the\n             Investigator, could influence the outcome of the study;\n\n          -  True periodontal pockets of > 5 mm and/or visible recession indicative of attachment\n             loss;\n\n          -  Current signs or symptoms of mucosal tissue ulcerations or inflammation, or canker\n             sores;\n\n          -  Presence of orthodontic appliances or any removable appliance that impinges on the\n             oral tissues being assessed;\n\n          -  History of early onset periodontal disease or acute necrotizing ulcerative\n             gingivitis;\n\n          -  Subject reported history in past 6 months or current alcohol abuse that, in the\n             opinion of the Investigator, could influence the outcome of the study;\n\n          -  Subject reported history of last past 6 months or current drug abuse;\n\n          -  Chronic treatment (2 weeks or more) with any medication known to affect periodontal\n             status (including phenytoin, calcium antagonists, cyclosporine, coumarin,\n             non-steroidal antiinflammatory drugs, and aspirin) within 1 month of the screening\n             examination. All other medications for chronic medical conditions have been initiated\n             at least 3 months before enrollment;\n\n          -  Current use of a statin or the use of a statin within the past sixty (60) days of\n             screening;\n\n          -  Concomitant therapy with another investigational drug or device without prior\n             approval from the Sponsor within four weeks prior to Visit 2 (Study Day 1);\n\n          -  Concomitant endodontic or periodontal therapy other than prophylaxis in the past six\n             (6) months;\n\n          -  Females with childbearing potential with a positive pregnancy test, pregnant or\n             nursing mothers, suspected pregnancy, or intention to become pregnant during the\n             study;\n\n          -  Residence in the same household as a subject already enrolled in the study (inclusion\n             may create blinding and/or compliance issues);\n\n          -  Unable and unwilling to comply with the informed consent process, to meet study\n             requirements including following instructions on study intervention, and to return\n             for follow-up visits as required by the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "76", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01782170", 
            "org_study_id": "UK12-0972-F2L", 
            "secondary_id": "R44HL101821"
        }, 
        "intervention": [
            {
                "arm_group_label": "Iocide Oral Rinse", 
                "intervention_name": "Iocide Oral Rinse", 
                "intervention_type": "Drug", 
                "other_name": "Iocide Oral Rinse - once daily 30 second rinse for 24 weeks"
            }, 
            {
                "arm_group_label": "Placebo Control", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Gingivitis", 
            "Biomarkers", 
            "Biological Markers of Inflammation"
        ], 
        "lastchanged_date": "August 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lexington", 
                    "country": "United States", 
                    "state": "Kentucky", 
                    "zip": "40506"
                }, 
                "name": "University of Kentucky, Center for Oral Health Research, College of Dentistry"
            }, 
            "investigator": {
                "last_name": "Dolph Dawson, DMD, MS", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Study: Evaluate Efficacy of Iocide Oral Rinse in a Human Clinical Trial of Gingival Inflammation and Investigate Effects on Biological Markers Indicative of Systemic Disease", 
        "other_outcome": {
            "description": "The assessment of product safety will include the following: incidence of adverse events, measures of thyroid function, and iodine excretion.  Additionally, investigators will assess any development of opportunistic infection with Candida albicans, changes in oral tissues, and concomitant medication interactions.", 
            "measure": "Assessment of Product Safety", 
            "safety_issue": "Yes", 
            "time_frame": "Study Days 1 through Study Days 168"
        }, 
        "overall_contact": {
            "email": "hbwils00@uky.edu", 
            "last_name": "Hailey Gallivan, CCRP", 
            "phone": "859-323-4923"
        }, 
        "overall_contact_backup": {
            "email": "mccloskey@biodevcorp.com", 
            "last_name": "Karl McCloskey", 
            "phone": "(361) 442-7491"
        }, 
        "overall_official": {
            "affiliation": "University of Kentucky", 
            "last_name": "Dolphus R Dawson III, DMD, MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in Mean Gingival Index (GI)", 
            "safety_issue": "No", 
            "time_frame": "Study Days -21 to -7 through Study Day 168"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01782170"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change in Biological Marker Data", 
            "safety_issue": "No", 
            "time_frame": "Study Day 1, Day 28, Day 84 and Day 168"
        }, 
        "source": "Biomedical Development Corporation", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "University of Kentucky", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Biomedical Development Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}